Clinical trials: Glaucoma Open-angle
Glaucoma, Open Angle Glaucoma
Long-term Safety and Performance of the ARGOS-SC Suprachoroidal Pressure Sensor System in Patients With Glaucoma Underwent Non-penetrating Glaucoma Surgery
The purpose of this study is to evaluate the long-term safety and performance of the ARGOS-SC system.
- Trial name
- NCT04773106
- Testing
- ARGOS-SC suprachoroidal pressure sensor
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 22 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Glaucoma, Open-Angle
A Prospective, Multicenter Study of the OMNI® Surgical System in Pseudophakic Eyes With Open Angle Glaucoma
To prospectively assess the clinical effect of ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System in pseudophakic eyes on intraocular pressure (IOP) and the use of IOP-lowering…
- Trial name
- ORION (NCT04465630)
- Testing
- OMNI® Surgical System
- Where
- 11 sites in United States
- Volunteers
- 78 people
- Sponsor
- Sight Sciences, Inc.
Glaucoma, Ocular Hypertension
Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
The purpose of this study was to assess the safety and describe the steady-state plasma pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation) following a once daily administration for 7 days in…
- Trial name
- NCT01658839
- Testing
- Travoprost ophthalmic solution, 0.004% (new formulation)
- Volunteers
- 25 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy
The purpose of this study was to evaluate the safety and efficacy of adding AZARGA® as a single agent to prostaglandin monotherapy in patients with either ocular hypertension or primary open-angle glaucoma.
- Trial name
- NCT01263444
- Testing
- Brinzolamide 1% / timolol 0.5% Fixed Combination, Habitual prostaglandin monotherapy
- Volunteers
- 47 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
The purpose of this study is to compare the fixed combination (BID) [Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL eyes drops, suspension] to the unfixed combination (BID) [Brinzolamide 10 mg/mL eye drops, suspension plus…
- Trial name
- NCT02339584
- Testing
- Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension, Brinzolamide 10 mg/mL eye drops, suspension, Brimonidine 2 mg/mL eye drops, solution
- Volunteers
- 493 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)
This study will test the hypothesis that preservative-free tafluprost (MK-2452) is non-inferior to preservative-free timolol maleate with respect to the diurnal intraocular pressure (IOP) change from baseline after 4 weeks of…
- Trial name
- NCT01254604
- Testing
- Preservative-Free Tafluprost or vehicle, Preservative-Free Timolol maleate
- Volunteers
- 190 people
- Sponsor
- Merck Sharp & Dohme LLC
Open-Angle Glaucoma, Ocular Hypertension
Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension
The purpose of this study was to evaluate the safety and efficacy of Brinzolamide/Brimonidine in lowering intraocular pressure (IOP) relative to each of its individual active components in patients with open-angle glaucoma or…
- Trial name
- NCT01310777
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide 1% ophthalmic suspension, Brimonidine tartrate 0.2% ophthalmic solution
- Volunteers
- 771 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
In participants with a diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT), the primary objective is to demonstrate that the mean IOP reduction after 3 months of treatment with BOL-303259-X once daily (QD) is…
- Trial name
- LUNAR (NCT01749930)
- Testing
- BOL-303259-X, Timolol
- Where
- United States
- Volunteers
- 420 people
- Sponsor
- Bausch & Lomb Incorporated
Open-angle Glaucoma, Ocular Hypertension
A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs
The objective of the study was to evaluate whether timolol hemihydrate is more comfortable upon instillation than timolol maleate in sorbate. This was an observational study.
- Trial name
- NCT00823043
- Testing
- timolol hemihydrate, timolol maleate
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Vistakon Pharmaceuticals
Primary Open-Angle Glaucoma, Ocular Hypertension
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
This study evaluated the long-term (9-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-004.
- Trial name
- OLE2 (NCT02537015)
- Testing
- Bimatoprost
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- ForSight Vision5, Inc.
Graft vs Host Disease, Congenital Aniridia
Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation
The ARGOS-IO pressure sensor is intended to be implanted in the human eye in combination with Boston Keratoprosthesis (BKPro) surgery and to remain in place indefinitely.
- Conditions
- Graft vs Host Disease, Congenital Aniridia, Chemical Burns, Stevens-Johnson Syndrome
- Trial name
- NCT02945176
- Testing
- ARGOS-IO system
- Where
- 2 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Sleep Apnea, Obstructive, Primary Open-angle Glaucoma
IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure
Sleep apnea is characterized by repetitive episodes of decreased or interrupted airflow in the upper airways during sleep. Obstructive sleep apnea syndrome (OSAS) is the most common sleep-related breathing disorder and is…
- Trial name
- NCT01560975
- Testing
- SENSIMED Triggerfish®
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sensimed AG
Primary Open Angle Glaucoma, Ocular Hypertension
Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Reduction of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for…
- Trial name
- ANGEL-2 (NCT04742283)
- Testing
- DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
- Where
- 41 sites in United States
- Volunteers
- 323 people
- Sponsor
- Santen Inc.
Glaucoma
Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)
We have completed a study in which we examined the response of the retinal circulation to changes in posture from sitting to lying down in patients with primary open angle glaucoma (POAG).
- Trial name
- NCT00824824
- Testing
- Dorzolamide 2%-timolol 0.5%, Brimonidine 0.2%-0.5% timolol 0.5
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Primary Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
This is a Phase 3 study to evaluate the safety and efficacy of T-2345 dosed to one of both eyes once daily for 84 days compared to Xalatan dosed to one of both eyes once daily for 84 days in patients with elevated eye pressure.
- Trial name
- NCT02059278
- Testing
- T-2345, Xalatan
- Where
- United States
- Volunteers
- 335 people
- Sponsor
- Nephron Pharmaceuticals Corporation
Primary Open-angle Glaucoma (POAG) Patient
Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients
The purpose of this study is to investigate how the intraocular pressure (IOP) varies in time and if the IOP variations are associated with the worsening of glaucoma.
- Trial name
- NCT01828255
- Testing
- SENSIMED Triggerfish®
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sensimed AG
Primary Open Angle Glaucoma
Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant
To assess the safety and performance of the MIDI Arrow in patients suffering from glaucoma that is inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥ 18 mm Hg and ≤ 40 mm Hg
- Trial name
- NCT01563237
- Testing
- MIDI Arrow
- Where
- France
- Volunteers
- 69 people
- Sponsor
- InnFocus Inc.
Ocular Hypertension, Open Angle Glaucoma
BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension
This clinical investigation is being performed to compare the effect of BOL-303259-X dosed once daily (QD) with timolol maleate 0.5% dosed twice daily (BID) in reducing intraocular pressure (IOP) measured over a 24-hour period in…
- Trial name
- Constellation (NCT01707381)
- Testing
- BOL-303259-X, Timolol maleate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Bausch & Lomb Incorporated
Glaucoma, Ocular Hypertension
Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT02167035
- Testing
- Combigan Two Times Daily (BID), Simbrinza Three Times Daily (TID)
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Cornerstone Health Care, PA
Glaucoma and Ocular Hypertension
Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma
This is a multiple cohort study that will evaluate the safety and efficacy of ENV515 travoprost XR in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02371746
- Testing
- ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR
- Where
- 14 sites in United States
- Volunteers
- 41 people
- Sponsor
- Envisia Therapeutics